University of York: Centre for Reviews and Dissemination
Are you: Mapping upcoming biosimilar and generic entry timelines
Subcutaneous SMG (2.4 mg) is cost-effective in reducing weight in individuals with obesity or overweight associated with comorbidities when compared with a group with no treatment, a group with only diet and exercise, and all other groups with other anti-obesity drugs (liraglutide 3 mg, phentermine-topiramate, and naltrexone-bupropion) [162]
End-of-week blood glucose variations are typically caused by lifestyle factors such as changes in diet, physical activity, stress levels, or sleep quality rather than the medication wearing off
Its application extends to the hospital environment, specialized clinics, and even in patients' homes, through means of administration that include injectors and pills